Lilly Asia Ventures has returned to reinvest in the renal disease therapy developer through a series B-plus round totalling $54.5m.

China-based renal disease therapy developer Alebund Pharmaceuticals has completed a $54.5m series B-plus round that included Lilly Asia Ventures, a corporate venturing unit for pharmaceutical firm Eli Lilly, DealStreetAsia reported yesterday.

Venture capital firm 3H Health Investment and investment firm Morningside co-led the round alongside private equity firm Loyal Valley Capital.

YuanBio Venture Capital, Octagon Capital, Verition Fund Management, HT Capital, Quan Capital, 3E Bioventures Capital, Sherpa Healthcare Partners and an unnamed sovereign wealth fund filled out the list of…